Q2 2025 · 13F-HR
Sofinnova Investments, Inc.holdings as filed
Filed 2025-08-14 · accession 0001104659-25-078481
$1.64B
Reported value
63
Positions
2025-06-30
Period end
The Brief · Sofinnova Investments, Inc. · Q2 2025
AI · grounded in 13F
Sofinnova Investments, Inc. established a new position in Natera Inc NTRA valued at $261.9M. The fund also initiated new stakes in Gilead Sciences Inc GILD for $116.4M and Eli Lilly and Co LLY for $75.6M. Other new additions include Jazz Pharmaceuticals PLC JAZZ and Vera Therapeutics Inc VERA. Total assets under management stand at $1.6B across 58 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 632307104 | NTRA | Natera Inc | $261.9M | 16.0% | 1,550,280 | Common | SOLE |
| 375558103 | GILD | Gilead Sciences Inc | $116.4M | 7.12% | 1,050,308 | Common | SOLE |
| 532457108 | LLY | Eli Lilly and Co | $75.6M | 4.63% | 97,018 | Common | SOLE |
| G50871105 | JAZZ | Jazz Pharmaceuticals PLC | $73.7M | 4.50% | 694,096 | Common | SOLE |
| 92337R101 | VERA | Vera Therapeutics Inc | $65.8M | 4.03% | 2,793,987 | Common | SOLE |
| 464287655 | IWM | iShares TR | $53.9M | 3.30% | 250,000 | PUT | SOLE |
| 00287Y109 | ABBV | AbbVie Inc | $49.3M | 3.02% | 265,850 | Common | SOLE |
| 464287556 | IBB | iShares TR | $47.4M | 2.90% | 375,000 | PUT | SOLE |
| 101137107 | BSX | Boston Scientific Corp | $46.3M | 2.83% | 431,200 | Common | SOLE |
| 252131107 | DXCM | Dexcom Inc | $45.7M | 2.80% | 523,694 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA Biosciences Inc | $45.1M | 2.76% | 2,147,795 | Common | SOLE |
| 10806X102 | BBIO | BridgeBio Pharma Inc | $42.9M | 2.62% | 993,093 | Common | SOLE |
| 46120E602 | ISRG | Intuitive Surgical Inc | $38.4M | 2.35% | 70,642 | Common | SOLE |
| 76243J105 | RYTM | Rhythm Pharmaceuticals Inc | $37.0M | 2.26% | 586,010 | Common | SOLE |
| 04272N102 | AVBP | Arrivent BioPharma Inc | $36.9M | 2.26% | 1,696,752 | Common | SOLE |
| G76279101 | ROIV | Roivant Sciences Ltd | $34.8M | 2.13% | 3,088,814 | Common | SOLE |
| 834203309 | SLNO | Soleno Therapeutics Inc | $34.8M | 2.13% | 415,219 | Common | SOLE |
| 91307C102 | UTHR | United Therapeutics Corp | $34.1M | 2.08% | 118,513 | Common | SOLE |
| 457669307 | INSM | Insmed Inc | $31.6M | 1.93% | 313,923 | Common | SOLE |
| 00973Y108 | AKRO | Akero Therapeutics Inc | $29.3M | 1.79% | 548,788 | Common | SOLE |
| 868459108 | SUPN | Supernus Pharmaceuticals Inc | $25.2M | 1.54% | 799,253 | Common | SOLE |
| 032724106 | ANAB | AnaptysBio Inc | $22.9M | 1.40% | 1,032,362 | Common | SOLE |
| 75383L102 | RAPP | Rapport Therapeutics Inc | $22.7M | 1.39% | 1,995,594 | Common | SOLE |
| N90064101 | QURE | Uniqure NV | $21.7M | 1.33% | 1,558,356 | Common | SOLE |
| N5749R100 | 2GH | Merus N V | $21.3M | 1.30% | 404,562 | Common | SOLE |
| 046353108 | AZNN | AstraZeneca PLC | $20.5M | 1.26% | 293,661 | Common | SOLE |
| 69366J200 | PTCT | PTC Therapeutics Inc | $18.4M | 1.12% | 375,939 | Common | SOLE |
| 45790W108 | — | Inozyme Pharma Inc | $17.1M | 1.05% | 4,280,308 | Common | SOLE |
| 19240Q201 | COGT | Cogent Biosciences Inc | $16.9M | 1.03% | 2,355,505 | Common | SOLE |
| 76029N106 | REPL | Replimune Group Inc | $16.8M | 1.03% | 1,806,529 | Common | SOLE |
| 05370A108 | RNAGBP | Avidity Biosciences Inc | $16.6M | 1.02% | 584,801 | Common | SOLE |
| 86627T108 | SMMT | Summit Therapeutics Inc | $14.9M | 0.91% | 700,000 | CALL | SOLE |
| 87164F105 | SNDX | Syndax Pharmaceuticals Inc | $14.3M | 0.87% | 1,524,440 | Common | SOLE |
| 76243J105 | RYTM | Rhythm Pharmaceuticals Inc | $14.2M | 0.87% | 225,000 | PUT | SOLE |
| 76029N106 | REPL | Replimune Group Inc | $13.9M | 0.85% | 1,500,000 | PUT | SOLE |
| 171757206 | CDTX | Cidara Therapeutics Inc | $12.2M | 0.75% | 251,031 | Common | SOLE |
| N44445109 | IMTX | Immatics N.V | $12.1M | 0.74% | 2,240,528 | Common | SOLE |
| G76279101 | ROIV | Roivant Sciences Ltd | $11.3M | 0.69% | 1,000,000 | CALL | SOLE |
| 30063P105 | EXK | Exact Sciences Corp | $11.1M | 0.68% | 208,300 | Common | SOLE |
| N69605108 | PHVS | Pharvaris N V | $10.3M | 0.63% | 585,532 | Common | SOLE |
| 45720N103 | INBX | Inhibrx Biosciences Inc | $10.1M | 0.62% | 708,678 | Common | SOLE |
| 03969F109 | RCUS | Arcus Biosciences Inc | $9.9M | 0.61% | 1,216,016 | Common | SOLE |
| 984241109 | YMABUSD | Y-mAbs Therapeutics Inc | $9.9M | 0.61% | 2,194,278 | Common | SOLE |
| 05464T104 | AXSM | Axsome Therapeutics Inc | $9.8M | 0.60% | 93,610 | Common | SOLE |
| 09077V100 | BIOA | BioAge Labs Inc | $9.5M | 0.58% | 2,304,901 | Common | SOLE |
| 28036F105 | EWTX | Edgewise Therapeutics Inc | $9.4M | 0.57% | 716,873 | Common | SOLE |
| 45257U108 | IMNM | Immunome Inc | $7.2M | 0.44% | 778,476 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics Inc | $5.9M | 0.36% | 614,865 | Common | SOLE |
| 805111101 | SVRA | Savara Inc | $5.6M | 0.34% | 2,457,352 | Common | SOLE |
| 171757206 | CDTX | Cidara Therapeutics Inc | $4.9M | 0.30% | 100,000 | CALL | SOLE |
| 19240Q201 | COGT | Cogent Biosciences Inc | $4.7M | 0.29% | 660,000 | CALL | SOLE |
| 03770N101 | APGE | Apogee Therapeutics Inc | $3.3M | 0.20% | 76,180 | Common | SOLE |
| 65343E108 | NXTCEUR | Nextcure Inc | $1.2M | 0.08% | 2,671,856 | Common | SOLE |
| G31249108 | ESTA | Establishment Labs Hldgs Inc | $1.2M | 0.07% | 28,120 | Common | SOLE |
| 008064206 | JBIO | Jade Biosciences Inc | $1.1M | 0.07% | 107,391 | Common | SOLE |
| 59267L107 | — | Metsera Inc | $1.0M | 0.06% | 36,191 | Common | SOLE |
| 80706P103 | SRRK | Scholar Rock Hldg Corp | $936,505 | 0.06% | 26,440 | Common | SOLE |
| 097702203 | BOLT | Bolt Biotherapeutics Inc | $794,650 | 0.05% | 137,721 | Common | SOLE |
| Y95308105 | WVE | Wave Life Sciences Ltd | $766,370 | 0.05% | 117,903 | Common | SOLE |
| 86366E106 | GPCR | Structure Therapeutics Inc | $712,481 | 0.04% | 34,353 | Common | SOLE |
| 74006W207 | PRAX | Praxis Precision Medicines Inc | $660,900 | 0.04% | 15,717 | Common | SOLE |
| 45175G108 | — | Ikena Oncology Inc | $512,705 | 0.03% | 382,616 | Common | SOLE |
| 254604101 | IRON | Disc Medicine Inc | $387,244 | 0.02% | 7,312 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.